Download PDF
Semin Respir Crit Care Med 2016; 37(06): 886-896
DOI: 10.1055/s-0036-1592127
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Severity Assessment and the Immediate and Long-Term Prognosis in Community-Acquired Pneumonia

Martin Kolditz
1   Division of Pulmonology, Medical Department I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
,
Dionne Braeken
2   Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
,
Santiago Ewig
3   Thoraxzentrum Ruhrgebiet, Klinik für Pneumologie und Infektiologie, EVK Herne und Augusta-Kranken-Anstalt Bochum, Bochum, Germany
,
Gernot Rohde
2   Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
13 December 2016 (online)

    Permissions and Reprints

Abstract

Severity assessment is a crucial step in the initial management of patients with community-acquired pneumonia (CAP). While approximately half of patients are at low risk of death and can be safely treated as outpatients, around 20% are at increased risk. While CURB-65 (confusion, respiratory rate, blood pressure, urea) and pneumonia severity index (PSI) scores are equally useful as an adjunct to clinical judgment to identify patients at low risk, the so-called minor American Thoracic Society/Infectious Diseases Society of America criteria are predictive of patients in need of intensified treatment (i.e., mechanical ventilation and/or vasopressor treatment). Such patients represent medical emergencies. In elderly patients, CRB-65 (confusion, respiratory rate, blood pressure, age) is no longer predictive of low risk; instead, poor functional status is the best predictor of death. In addition to scores, assessment of oxygenation and unstable comorbidity, as well as lactate and biomarkers remain important to consider. The added value of combined clinical and biomarker risk stratification strategies should be evaluated in large prospective interventional trials.

Survivors of hospitalized CAP have a considerable excess long-term mortality. Risk factors include age, male gender, and nursing home residency, as well as increased PSI and CURB-65 scores. Cardiovascular, pulmonary, renal, and neoplastic comorbidities are prominent causes of long-term mortality. Comorbidities are vulnerable to both the acute and chronic subclinical inflammatory challenge delivered by pulmonary infection and are thereby drivers of mortality. Biomarkers are promising in identifying patients at increased risk of long-term mortality. Future studies should develop consistent strategies of risk stratification and intervention to improve long-term outcomes of patients with CAP.

Keywords

community acquired pneumonia - pneumonia severity index - risk stratification - mortality - CURB-65
 

  • References

  • 1 Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67 (1) 71-79
    CrossrefPubMedGoogle Scholar
  • 2 Bauer TT, Ewig S, Marre R, Suttorp N, Welte T ; CAPNETZ Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006; 260 (1) 93-101
    CrossrefPubMedGoogle Scholar
  • 3 Carratalà J, Fernández-Sabé N, Ortega L , et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005; 142 (3) 165-172
    CrossrefPubMedGoogle Scholar
  • 4 Renaud B, Coma E, Labarere J , et al; Pneumocom Study Investigators. Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis 2007; 44 (1) 41-49
    CrossrefPubMedGoogle Scholar
  • 5 Akram AR, Chalmers JD, Hill AT. Predicting mortality with severity assessment tools in out-patients with community-acquired pneumonia. QJM 2011; 104 (10) 871-879
    CrossrefPubMedGoogle Scholar
  • 6 McNally M, Curtain J, O'Brien KK, Dimitrov BD, Fahey T. Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysis. Br J Gen Pract 2010; 60 (579) e423-e433
    CrossrefPubMedGoogle Scholar
  • 7 Ewig S, Birkner N, Strauss R , et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64 (12) 1062-1069
    CrossrefPubMedGoogle Scholar
  • 8 Aliberti S, Brambilla AM, Chalmers JD , et al. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respir Res 2014; 15: 27
    CrossrefPubMedGoogle Scholar
  • 9 Kolditz M, Ewig S, Klapdor B , et al; CAPNETZ study group. Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax 2015; 70 (6) 551-558
    CrossrefPubMedGoogle Scholar
  • 10 Kolditz M, Bauer TT, König T, Rohde G, Ewig S. 3-day mortality in hospitalised community-acquired pneumonia: frequency and risk factors. Eur Respir J 2016; 47 (5) 1572-1574
    CrossrefPubMedGoogle Scholar
  • 11 Mandell LA, Wunderink RG, Anzueto A , et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 02) S27-S72
    CrossrefPubMedGoogle Scholar
  • 12 Woodhead M, Blasi F, Ewig S , et al; Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect 2011; 17 (Suppl. 06) E1-E59
    PubMedGoogle Scholar
  • 13 Ewig S, Höffken G, Kern WV , et al. Management of adult community-acquired pneumonia and prevention - update 2016 [in German]. Pneumologie 2016; 70 (3) 151-200
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Fine MJ, Auble TE, Yealy DM , et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336 (4) 243-250
    CrossrefPubMedGoogle Scholar
  • 15 Lim WS, van der Eerden MM, Laing R , et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58 (5) 377-382
    CrossrefPubMedGoogle Scholar
  • 16 Chalmers JD, Singanayagam A, Akram AR , et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax 2010; 65 (10) 878-883
    CrossrefPubMedGoogle Scholar
  • 17 Loke YK, Kwok CS, Niruban A, Myint PK. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax 2010; 65 (10) 884-890
    CrossrefPubMedGoogle Scholar
  • 18 Choudhury G, Chalmers JD, Mandal P , et al. Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J 2011; 38 (3) 643-648
    CrossrefPubMedGoogle Scholar
  • 19 Majumdar SR, Eurich DT, Gamble JM, Senthilselvan A, Marrie TJ. Oxygen saturations less than 92% are associated with major adverse events in outpatients with pneumonia: a population-based cohort study. Clin Infect Dis 2011; 52 (3) 325-331
    CrossrefPubMedGoogle Scholar
  • 20 Halm EA, Atlas SJ, Borowsky LH , et al. Understanding physician adherence with a pneumonia practice guideline: effects of patient, system, and physician factors. Arch Intern Med 2000; 160 (1) 98-104
    CrossrefPubMedGoogle Scholar
  • 21 Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283 (6) 749-755
    CrossrefPubMedGoogle Scholar
  • 22 Ewig S, Welte T. CRB-65 for the assessment of pneumonia severity: who could ask for more?. Thorax 2008; 63 (8) 665-666
    CrossrefPubMedGoogle Scholar
  • 23 Ewig S, Bauer T, Richter K , et al. Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups. Eur Respir J 2013; 41 (4) 917-922
    CrossrefPubMedGoogle Scholar
  • 24 Kolditz M, Ewig S, Schütte H, Suttorp N, Welte T, Rohde G ; CAPNETZ study group. Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med 2015; 278 (2) 193-202
    CrossrefPubMedGoogle Scholar
  • 25 Dwyer R, Hedlund J, Darenberg J , et al. Improvement of CRB-65 as a prognostic scoring system in adult patients with bacteraemic pneumococcal pneumonia. Scand J Infect Dis 2011; 43 (6–7) 448-455
    CrossrefPubMedGoogle Scholar
  • 26 Dwyer R, Hedlund J, Henriques-Normark B, Kalin M. Improvement of CRB-65 as a prognostic tool in adult patients with community-acquired pneumonia. BMJ Open Respir Res 2014; 1 (1) e000038
    PubMedGoogle Scholar
  • 27 Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012; 125 (6) 773-781
    CrossrefPubMedGoogle Scholar
  • 28 Aliberti S, Ramirez J, Cosentini R , et al. Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia. ERJ Open Res 2015; 1: 00020-02015
    PubMedGoogle Scholar
  • 29 El-Solh AA, Alhajhusain A, Abou Jaoude P, Drinka P. Validity of severity scores in hospitalized patients with nursing home-acquired pneumonia. Chest 2010; 138 (6) 1371-1376
    CrossrefPubMedGoogle Scholar
  • 30 Bauer TT, Welte T, Strauss R, Bischoff H, Richter K, Ewig S. Why do nonsurvivors from community-acquired pneumonia not receive ventilatory support?. Lung 2013; 191 (4) 417-424
    CrossrefPubMedGoogle Scholar
  • 31 Zeymer U, Hambrecht R, Theres H , et al. Treatment of ST-segment elevation acute myocardial infarction in hospitals with and without cardiac catheterization laboratory [in German]. Dtsch Med Wochenschr 2013; 138 (39) 1935-1940
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Ewig S, Torres A. Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality. Eur Respir J 2011; 38 (2) 253-260
    CrossrefPubMedGoogle Scholar
  • 33 Ewig S, Woodhead M, Torres A. Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med 2011; 37 (2) 214-223
    CrossrefPubMedGoogle Scholar
  • 34 Chalmers JD, Taylor JK, Mandal P , et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 2011; 53 (6) 503-511
    CrossrefPubMedGoogle Scholar
  • 35 Salih W, Schembri S, Chalmers JD. Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data. Eur Respir J 2014; 43 (3) 842-851
    CrossrefPubMedGoogle Scholar
  • 36 Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course?. Chest 2006; 129 (4) 968-978
    CrossrefPubMedGoogle Scholar
  • 37 Phua J, Ngerng WJ, Lim TK. The impact of a delay in intensive care unit admission for community-acquired pneumonia. Eur Respir J 2010; 36 (4) 826-833
    CrossrefPubMedGoogle Scholar
  • 38 Renaud B, Santin A, Coma E , et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit Care Med 2009; 37 (11) 2867-2874
    CrossrefPubMedGoogle Scholar
  • 39 Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010; 137 (3) 552-557
    CrossrefPubMedGoogle Scholar
  • 40 Delgado MK, Liu V, Pines JM, Kipnis P, Gardner MN, Escobar GJ. Risk factors for unplanned transfer to intensive care within 24 hours of admission from the emergency department in an integrated healthcare system. J Hosp Med 2013; 8 (1) 13-19
    CrossrefPubMedGoogle Scholar
  • 41 Lim HF, Phua J, Mukhopadhyay A , et al. IDSA/ATS minor criteria aid pre-intensive care unit resuscitation in severe community-acquired pneumonia. Eur Respir J 2014; 43 (3) 852-862
    CrossrefPubMedGoogle Scholar
  • 42 Ferrer R, Martin-Loeches I, Phillips G , et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42 (8) 1749-1755
    CrossrefPubMedGoogle Scholar
  • 43 Chamberlain DJ, Willis EM, Bersten AB. The severe sepsis bundles as processes of care: a meta-analysis. Aust Crit Care 2011; 24 (4) 229-243
    CrossrefPubMedGoogle Scholar
  • 44 Gattarello S, Borgatta B, Solé-Violán J , et al; Community-Acquired Pneumonia en la Unidad de Cuidados Intensivos II Study Investigators. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013). Chest 2014; 146 (1) 22-31
    CrossrefPubMedGoogle Scholar
  • 45 Hortmann M, Heppner HJ, Popp S, Lad T, Christ M. Reduction of mortality in community-acquired pneumonia after implementing standardized care bundles in the emergency department. Eur J Emerg Med 2014; 21 (6) 429-435
    CrossrefPubMedGoogle Scholar
  • 46 Guo Q, Li HY, Li YM , et al. Compliance with severe sepsis bundles and its effect on patient outcomes of severe community-acquired pneumonia in a limited resources country. Arch Med Sci 2014; 10 (5) 970-978
    PubMedGoogle Scholar
  • 47 Kolditz M, Ewig S, Höffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 2013; 41 (4) 974-984
    CrossrefPubMedGoogle Scholar
  • 48 Ewig S, Ruiz M, Mensa J , et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998; 158 (4) 1102-1108
    CrossrefPubMedGoogle Scholar
  • 49 Charles PG, Wolfe R, Whitby M , et al; Australian Community-Acquired Pneumonia Study Collaboration. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47 (3) 375-384
    CrossrefPubMedGoogle Scholar
  • 50 España PP, Capelastegui A, Gorordo I , et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006; 174 (11) 1249-1256
    CrossrefPubMedGoogle Scholar
  • 51 Yandiola PP, Capelastegui A, Quintana J , et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest 2009; 135 (6) 1572-1579
    CrossrefPubMedGoogle Scholar
  • 52 Buising KL, Thursky KA, Black JF , et al. Identifying severe community-acquired pneumonia in the emergency department: a simple clinical prediction tool. Emerg Med Australas 2007; 19 (5) 418-426
    CrossrefPubMedGoogle Scholar
  • 53 Renaud B, Labarère J, Coma E , et al. Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. Crit Care 2009; 13 (2) R54
    CrossrefPubMedGoogle Scholar
  • 54 Labarère J, Schuetz P, Renaud B, Claessens YE, Albrich W, Mueller B. Validation of a clinical prediction model for early admission to the intensive care unit of patients with pneumonia. Acad Emerg Med 2012; 19 (9) 993-1003
    CrossrefPubMedGoogle Scholar
  • 55 Chalmers JD, Mandal P, Singanayagam A , et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 2011; 37 (9) 1409-1420
    CrossrefPubMedGoogle Scholar
  • 56 Marti C, Garin N, Grosgurin O , et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care 2012; 16 (4) R141
    CrossrefPubMedGoogle Scholar
  • 57 Suetrong B, Walley KR. Lactic acidosis in sepsis: it's not all anaerobic: implications for diagnosis and management. Chest 2016; 149 (1) 252-261
    CrossrefPubMedGoogle Scholar
  • 58 Tang Y, Choi J, Kim D , et al. Clinical predictors of adverse outcome in severe sepsis patients with lactate 2-4 mM admitted to the hospital. QJM 2015; 108 (4) 279-287
    CrossrefPubMedGoogle Scholar
  • 59 Casserly B, Phillips GS, Schorr C , et al. Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. Crit Care Med 2015; 43 (3) 567-573
    CrossrefPubMedGoogle Scholar
  • 60 Shankar-Hari M, Phillips GS, Levy ML , et al; Sepsis Definitions Task Force. Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315 (8) 775-787
    CrossrefPubMedGoogle Scholar
  • 61 Jansen TC, van Bommel J, Schoonderbeek FJ , et al; LACTATE study group. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med 2010; 182 (6) 752-761
    CrossrefPubMedGoogle Scholar
  • 62 Dettmer M, Holthaus CV, Fuller BM. The impact of serial lactate monitoring on emergency department resuscitation interventions and clinical outcomes in severe sepsis and septic shock: an observational cohort study. Shock 2015; 43 (1) 55-61
    CrossrefPubMedGoogle Scholar
  • 63 Singer M, Deutschman CS, Seymour CW , et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315 (8) 801-810
    CrossrefPubMedGoogle Scholar
  • 64 Gwak MH, Jo S, Jeong T , et al. Initial serum lactate level is associated with inpatient mortality in patients with community-acquired pneumonia. Am J Emerg Med 2015; 33 (5) 685-690
    CrossrefPubMedGoogle Scholar
  • 65 Liu B, Yin Q, Chen YX, Zhao YZ, Li CS. Role of Presepsin (sCD14-ST) and the CURB65 scoring system in predicting severity and outcome of community-acquired pneumonia in an emergency department. Respir Med 2014; 108 (8) 1204-1213
    CrossrefPubMedGoogle Scholar
  • 66 Chen YX, Li CS. Lactate on emergency department arrival as a predictor of mortality and site-of-care in pneumonia patients: a cohort study. Thorax 2015; 70 (5) 404-410
    CrossrefPubMedGoogle Scholar
  • 67 Jo S, Jeong T, Lee JB, Jin Y, Yoon J, Park B. Validation of modified early warning score using serum lactate level in community-acquired pneumonia patients. The National Early Warning Score-Lactate score. Am J Emerg Med 2016; 34 (3) 536-541
    CrossrefPubMedGoogle Scholar
  • 68 Halm EA, Fine MJ, Marrie TJ , et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279 (18) 1452-1457
    CrossrefPubMedGoogle Scholar
  • 69 Carratalà J, Garcia-Vidal C, Ortega L , et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med 2012; 172 (12) 922-928
    PubMedGoogle Scholar
  • 70 Lepper PM, Ott S, Nüesch E , et al; German Community Acquired Pneumonia Competence Network. Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ 2012; 344: e3397
    CrossrefPubMedGoogle Scholar
  • 71 Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121 (3) 219-225
    CrossrefPubMedGoogle Scholar
  • 72 Krüger S, Ewig S, Marre R , et al; CAPNETZ Study Group. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31 (2) 349-355
    CrossrefPubMedGoogle Scholar
  • 73 Ramírez P, Ferrer M, Martí V , et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011; 39 (10) 2211-2217
    CrossrefPubMedGoogle Scholar
  • 74 Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B ; Procalcitonin-Guided Antibiotic Therapy and Hospitalisation in Patients with Lower Respiratory Tract Infections (ProHOSP) Study Group. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 2011; 37 (2) 384-392
    CrossrefPubMedGoogle Scholar
  • 75 Charles PE, Tinel C, Barbar S , et al. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 2009; 13 (2) R38
    CrossrefPubMedGoogle Scholar
  • 76 Shehabi Y, Sterba M, Garrett PM , et al; ProGUARD Study Investigators; ANZICS Clinical Trials Group. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 2014; 190 (10) 1102-1110
    CrossrefPubMedGoogle Scholar
  • 77 Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008; 32 (3) 726-732
    CrossrefPubMedGoogle Scholar
  • 78 Coelho L, Póvoa P, Almeida E , et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007; 11 (4) R92-R100
    CrossrefPubMedGoogle Scholar
  • 79 Oliveira CF, Botoni FA, Oliveira CR , et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med 2013; 41 (10) 2336-2343
    CrossrefPubMedGoogle Scholar
  • 80 Schuetz P, Briel M, Mueller B. Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA 2013; 309 (7) 717-718
    CrossrefPubMedGoogle Scholar
  • 81 de Jong E, van Oers JA, Beishuizen A , et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16 (7) 819-827
    CrossrefPubMedGoogle Scholar
  • 82 Nowak A, Breidthardt T, Christ-Crain M , et al. Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia. Chest 2012; 141 (4) 974-982
    CrossrefPubMedGoogle Scholar
  • 83 Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T ; German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010; 182 (11) 1426-1434
    CrossrefPubMedGoogle Scholar
  • 84 Schuetz P, Wolbers M, Christ-Crain M , et al; ProHOSP Study Group. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010; 14 (3) R106
    CrossrefPubMedGoogle Scholar
  • 85 Kolditz M, Halank M, Schulte-Hubbert B, Bergmann S, Albrecht S, Höffken G. Copeptin predicts clinical deterioration and persistent instability in community-acquired pneumonia. Respir Med 2012; 106 (9) 1320-1328
    CrossrefPubMedGoogle Scholar
  • 86 Renaud B, Schuetz P, Claessens YE, Labarère J, Albrich W, Mueller B. Proadrenomedullin improves risk of early admission to ICU score for predicting early severe community-acquired pneumonia. Chest 2012; 142 (6) 1447-1454
    CrossrefPubMedGoogle Scholar
  • 87 España PP, Capelastegui A, Mar C , et al. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia. J Infect 2015; 70 (5) 457-466
    CrossrefPubMedGoogle Scholar
  • 88 Chalmers JD, Singanayagam A, Scally C, Hill AT. Admission D-dimer can identify low-risk patients with community-acquired pneumonia. Ann Emerg Med 2009; 53 (5) 633-638
    CrossrefPubMedGoogle Scholar
  • 89 Kolditz M, Halank M, Schulte-Hubbert B, Höffken G. Adrenal function is related to prognosis in moderate community-acquired pneumonia. Eur Respir J 2010; 36 (3) 615-621
    CrossrefPubMedGoogle Scholar
  • 90 Kolditz M, Höffken G, Martus P , et al; CAPNETZ study group. Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study. BMC Infect Dis 2012; 12 (1) 90
    CrossrefPubMedGoogle Scholar
  • 91 Viasus D, Del Rio-Pertuz G, Simonetti AF , et al. Biomarkers for predicting short-term mortality in community-acquired pneumonia: a systematic review and meta-analysis. J Infect 2016; 72 (3) 273-282
    CrossrefPubMedGoogle Scholar
  • 92 Albrich WC, Rüegger K, Dusemund F , et al. Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial. Eur Respir J 2013; 42 (4) 1064-1075
    CrossrefPubMedGoogle Scholar
  • 93 Torres A, Sibila O, Ferrer M , et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313 (7) 677-686
    CrossrefPubMedGoogle Scholar
  • 94 Frat JP, Thille AW, Mercat A , et al; FLORALI Study Group; REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015; 372 (23) 2185-2196
    CrossrefPubMedGoogle Scholar
  • 95 Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 2014; 42 (2) 420-432
    CrossrefPubMedGoogle Scholar
  • 96 Welte T, Dellinger RP, Ebelt H , et al. Concept for a study design in patients with severe community-acquired pneumonia: a randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study. Respir Med 2015; 109 (6) 758-767
    CrossrefPubMedGoogle Scholar
  • 97 Davenport EE, Burnham KL, Radhakrishnan J , et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 2016; 4 (4) 259-271
    CrossrefPubMedGoogle Scholar
  • 98 Holter JC, Ueland T, Jenum PA , et al. Risk factors for long-term mortality after hospitalization for community-acquired pneumonia: a 5-year prospective follow-up study. PLoS ONE 2016; 11 (2) e0148741
    CrossrefPubMedGoogle Scholar
  • 99 Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Ten-year mortality after community-acquired pneumonia. A prospective cohort. Am J Respir Crit Care Med 2015; 192 (5) 597-604
    CrossrefPubMedGoogle Scholar
  • 100 Yende S, D'Angelo G, Kellum JA , et al; GenIMS Investigators. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177 (11) 1242-1247
    CrossrefPubMedGoogle Scholar
  • 101 Johnstone J, Eurich DT, Majumdar SR, Jin Y, Marrie TJ. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore) 2008; 87 (6) 329-334
    CrossrefPubMedGoogle Scholar
  • 102 Bruns AH, Oosterheert JJ, Cucciolillo MC , et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. Clin Microbiol Infect 2011; 17 (5) 763-768
    CrossrefPubMedGoogle Scholar
  • 103 Kaplan V, Clermont G, Griffin MF , et al. Pneumonia: still the old man's friend?. Arch Intern Med 2003; 163 (3) 317-323
    CrossrefPubMedGoogle Scholar
  • 104 Bordon J, Wiemken T, Peyrani P , et al; CAPO Study Group. Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest 2010; 138 (2) 279-283
    CrossrefPubMedGoogle Scholar
  • 105 Mortensen EM, Kapoor WN, Chang CC, Fine MJ. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003; 37 (12) 1617-1624
    CrossrefPubMedGoogle Scholar
  • 106 Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, McKeever TM. Pneumonia mortality in a UK general practice population cohort. Eur J Public Health 2009; 19 (5) 521-526
    CrossrefPubMedGoogle Scholar
  • 107 Restrepo MI, Faverio P, Anzueto A. Long-term prognosis in community-acquired pneumonia. Curr Opin Infect Dis 2013; 26 (2) 151-158
    CrossrefPubMedGoogle Scholar
  • 108 Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, Schuetz P. Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur Respir J 2011; 37 (6) 1439-1446
    CrossrefPubMedGoogle Scholar
  • 109 Alan M, Grolimund E, Kutz A , et al; ProHOSP study group. Clinical risk scores and blood biomarkers as predictors of long-term outcome in patients with community-acquired pneumonia: a 6-year prospective follow-up study. J Intern Med 2015; 278 (2) 174-184
    CrossrefPubMedGoogle Scholar
  • 110 Cecere LM, Rubenfeld GD, Park DR, Root RK, Goss CH. Long-term survival after hospitalization for community-acquired and healthcare-associated pneumonia. Respiration 2010; 79 (2) 128-136
    CrossrefPubMedGoogle Scholar
  • 111 Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 2004; 169 (8) 910-914
    CrossrefPubMedGoogle Scholar